nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—endothelium—skin cancer	0.0598	0.198	CbGeAlD
Plerixafor—CXCR4—blood vessel—skin cancer	0.0552	0.183	CbGeAlD
Plerixafor—CXCR4—nipple—skin cancer	0.0399	0.132	CbGeAlD
Plerixafor—CXCR4—connective tissue—skin cancer	0.0283	0.0936	CbGeAlD
Plerixafor—CXCR4—epithelium—skin cancer	0.0269	0.0888	CbGeAlD
Plerixafor—CXCR4—mammalian vulva—skin cancer	0.0233	0.0771	CbGeAlD
Plerixafor—CXCR4—lymphoid tissue—skin cancer	0.0207	0.0684	CbGeAlD
Plerixafor—CXCR4—female reproductive system—skin cancer	0.0199	0.066	CbGeAlD
Plerixafor—Induration—Imiquimod—skin cancer	0.0191	0.0317	CcSEcCtD
Plerixafor—CXCR4—head—skin cancer	0.0167	0.0551	CbGeAlD
Plerixafor—Musculoskeletal pain—Vismodegib—skin cancer	0.0164	0.0273	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.0154	0.162	CbGpPWpGaD
Plerixafor—Platelet count decreased—Imiquimod—skin cancer	0.0144	0.0239	CcSEcCtD
Plerixafor—Induration—Bleomycin—skin cancer	0.0136	0.0225	CcSEcCtD
Plerixafor—CXCR4—lymph node—skin cancer	0.0117	0.0386	CbGeAlD
Plerixafor—CXCR4—Peptide GPCRs—MC1R—skin cancer	0.0108	0.114	CbGpPWpGaD
Plerixafor—Musculoskeletal pain—Vemurafenib—skin cancer	0.0102	0.0168	CcSEcCtD
Plerixafor—Inflammation—Imiquimod—skin cancer	0.00882	0.0146	CcSEcCtD
Plerixafor—Connective tissue disorder—Vismodegib—skin cancer	0.00801	0.0133	CcSEcCtD
Plerixafor—Swelling—Imiquimod—skin cancer	0.00704	0.0117	CcSEcCtD
Plerixafor—Arthralgia—Vismodegib—skin cancer	0.00604	0.01	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.006	0.00996	CcSEcCtD
Plerixafor—Nervous system disorder—Vismodegib—skin cancer	0.00568	0.00942	CcSEcCtD
Plerixafor—Skin disorder—Vismodegib—skin cancer	0.00563	0.00933	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00528	0.00876	CcSEcCtD
Plerixafor—Musculoskeletal pain—Temozolomide—skin cancer	0.00519	0.00861	CcSEcCtD
Plerixafor—Dyspepsia—Vismodegib—skin cancer	0.0051	0.00846	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—MC1R—skin cancer	0.00509	0.0535	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Vismodegib—skin cancer	0.005	0.0083	CcSEcCtD
Plerixafor—Fatigue—Vismodegib—skin cancer	0.00499	0.00829	CcSEcCtD
Plerixafor—Pain—Vismodegib—skin cancer	0.00495	0.00822	CcSEcCtD
Plerixafor—Constipation—Vismodegib—skin cancer	0.00495	0.00822	CcSEcCtD
Plerixafor—Connective tissue disorder—Vemurafenib—skin cancer	0.00495	0.00821	CcSEcCtD
Plerixafor—Inflammation—Fluorouracil—skin cancer	0.00487	0.00808	CcSEcCtD
Plerixafor—Gastrointestinal pain—Vismodegib—skin cancer	0.00474	0.00786	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TERT—skin cancer	0.0046	0.0484	CbGpPWpGaD
Plerixafor—Abdominal pain—Vismodegib—skin cancer	0.00458	0.0076	CcSEcCtD
Plerixafor—Erythema—Vemurafenib—skin cancer	0.00438	0.00727	CcSEcCtD
Plerixafor—Haemoglobin—Imiquimod—skin cancer	0.00432	0.00716	CcSEcCtD
Plerixafor—Haemorrhage—Imiquimod—skin cancer	0.00429	0.00713	CcSEcCtD
Plerixafor—Connective tissue disorder—Imiquimod—skin cancer	0.00422	0.007	CcSEcCtD
Plerixafor—Asthenia—Vismodegib—skin cancer	0.00416	0.00689	CcSEcCtD
Plerixafor—Pruritus—Vismodegib—skin cancer	0.0041	0.0068	CcSEcCtD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00399	0.0419	CbGpPWpGaD
Plerixafor—Diarrhoea—Vismodegib—skin cancer	0.00396	0.00658	CcSEcCtD
Plerixafor—Swelling—Fluorouracil—skin cancer	0.00389	0.00645	CcSEcCtD
Plerixafor—Immune system disorder—Imiquimod—skin cancer	0.00388	0.00644	CcSEcCtD
Plerixafor—Mental disorder—Imiquimod—skin cancer	0.00376	0.00624	CcSEcCtD
Plerixafor—Erythema—Imiquimod—skin cancer	0.00374	0.0062	CcSEcCtD
Plerixafor—Arthralgia—Vemurafenib—skin cancer	0.00373	0.00619	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00371	0.00615	CcSEcCtD
Plerixafor—Vomiting—Vismodegib—skin cancer	0.00368	0.00611	CcSEcCtD
Plerixafor—Rash—Vismodegib—skin cancer	0.00365	0.00606	CcSEcCtD
Plerixafor—Dermatitis—Vismodegib—skin cancer	0.00365	0.00605	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—PTCH2—skin cancer	0.0036	0.0378	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Vemurafenib—skin cancer	0.00358	0.00594	CcSEcCtD
Plerixafor—Inflammation—Docetaxel—skin cancer	0.00351	0.00583	CcSEcCtD
Plerixafor—Nervous system disorder—Vemurafenib—skin cancer	0.00351	0.00582	CcSEcCtD
Plerixafor—Skin disorder—Vemurafenib—skin cancer	0.00348	0.00577	CcSEcCtD
Plerixafor—Ill-defined disorder—Imiquimod—skin cancer	0.00347	0.00576	CcSEcCtD
Plerixafor—Nausea—Vismodegib—skin cancer	0.00344	0.00571	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00342	0.0359	CbGpPWpGaD
Plerixafor—Injection site reaction—Docetaxel—skin cancer	0.00339	0.00562	CcSEcCtD
Plerixafor—Malaise—Imiquimod—skin cancer	0.00337	0.00559	CcSEcCtD
Plerixafor—Syncope—Imiquimod—skin cancer	0.00335	0.00556	CcSEcCtD
Plerixafor—Loss of consciousness—Imiquimod—skin cancer	0.00329	0.00545	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00326	0.00541	CcSEcCtD
Plerixafor—Abdominal distension—Temozolomide—skin cancer	0.00324	0.00537	CcSEcCtD
Plerixafor—Arthralgia—Imiquimod—skin cancer	0.00318	0.00528	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00316	0.00525	CcSEcCtD
Plerixafor—Discomfort—Imiquimod—skin cancer	0.00314	0.00522	CcSEcCtD
Plerixafor—Dry mouth—Imiquimod—skin cancer	0.00311	0.00517	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00309	0.00513	CcSEcCtD
Plerixafor—Fatigue—Vemurafenib—skin cancer	0.00308	0.00512	CcSEcCtD
Plerixafor—Haemoglobin—Bleomycin—skin cancer	0.00307	0.00509	CcSEcCtD
Plerixafor—Constipation—Vemurafenib—skin cancer	0.00306	0.00508	CcSEcCtD
Plerixafor—Haemorrhage—Bleomycin—skin cancer	0.00305	0.00506	CcSEcCtD
Plerixafor—Shock—Imiquimod—skin cancer	0.003	0.00498	CcSEcCtD
Plerixafor—Nervous system disorder—Imiquimod—skin cancer	0.00299	0.00497	CcSEcCtD
Plerixafor—Skin disorder—Imiquimod—skin cancer	0.00296	0.00492	CcSEcCtD
Plerixafor—Hyperhidrosis—Imiquimod—skin cancer	0.00295	0.00489	CcSEcCtD
Plerixafor—Swelling—Docetaxel—skin cancer	0.0028	0.00465	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00278	0.00461	CcSEcCtD
Plerixafor—Insomnia—Imiquimod—skin cancer	0.00276	0.00458	CcSEcCtD
Plerixafor—CXCR4—HIV Life Cycle—ERCC2—skin cancer	0.00275	0.029	CbGpPWpGaD
Plerixafor—Paraesthesia—Imiquimod—skin cancer	0.00274	0.00455	CcSEcCtD
Plerixafor—Dyspnoea—Imiquimod—skin cancer	0.00272	0.00451	CcSEcCtD
Plerixafor—Dyspepsia—Imiquimod—skin cancer	0.00269	0.00446	CcSEcCtD
Plerixafor—Erythema—Bleomycin—skin cancer	0.00266	0.00441	CcSEcCtD
Plerixafor—Hypersensitivity—Vemurafenib—skin cancer	0.00264	0.00437	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Imiquimod—skin cancer	0.00263	0.00437	CcSEcCtD
Plerixafor—Fatigue—Imiquimod—skin cancer	0.00263	0.00437	CcSEcCtD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00262	0.0276	CbGpPWpGaD
Plerixafor—Pain—Imiquimod—skin cancer	0.00261	0.00433	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—MC1R—skin cancer	0.0026	0.0273	CbGpPWpGaD
Plerixafor—Haemoglobin—Temozolomide—skin cancer	0.00259	0.00429	CcSEcCtD
Plerixafor—Haemorrhage—Temozolomide—skin cancer	0.00257	0.00427	CcSEcCtD
Plerixafor—Asthenia—Vemurafenib—skin cancer	0.00257	0.00426	CcSEcCtD
Plerixafor—Pruritus—Vemurafenib—skin cancer	0.00253	0.0042	CcSEcCtD
Plerixafor—Connective tissue disorder—Temozolomide—skin cancer	0.00253	0.0042	CcSEcCtD
Plerixafor—Feeling abnormal—Imiquimod—skin cancer	0.00251	0.00417	CcSEcCtD
Plerixafor—Gastrointestinal pain—Imiquimod—skin cancer	0.0025	0.00414	CcSEcCtD
Plerixafor—Erythema—Dactinomycin—skin cancer	0.00248	0.00411	CcSEcCtD
Plerixafor—Ill-defined disorder—Bleomycin—skin cancer	0.00246	0.00409	CcSEcCtD
Plerixafor—Diarrhoea—Vemurafenib—skin cancer	0.00245	0.00406	CcSEcCtD
Plerixafor—Urticaria—Imiquimod—skin cancer	0.00242	0.00402	CcSEcCtD
Plerixafor—Abdominal pain—Imiquimod—skin cancer	0.00241	0.004	CcSEcCtD
Plerixafor—Malaise—Bleomycin—skin cancer	0.0024	0.00397	CcSEcCtD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL6—skin cancer	0.00239	0.0252	CbGpPWpGaD
Plerixafor—Haemoglobin—Fluorouracil—skin cancer	0.00238	0.00395	CcSEcCtD
Plerixafor—Haemorrhage—Fluorouracil—skin cancer	0.00237	0.00393	CcSEcCtD
Plerixafor—Dizziness—Vemurafenib—skin cancer	0.00237	0.00393	CcSEcCtD
Plerixafor—Immune system disorder—Temozolomide—skin cancer	0.00232	0.00386	CcSEcCtD
Plerixafor—Ill-defined disorder—Dactinomycin—skin cancer	0.0023	0.00381	CcSEcCtD
Plerixafor—Vomiting—Vemurafenib—skin cancer	0.00227	0.00377	CcSEcCtD
Plerixafor—Orthostatic hypotension—Docetaxel—skin cancer	0.00226	0.00375	CcSEcCtD
Plerixafor—Rash—Vemurafenib—skin cancer	0.00226	0.00374	CcSEcCtD
Plerixafor—Mental disorder—Temozolomide—skin cancer	0.00225	0.00374	CcSEcCtD
Plerixafor—Dermatitis—Vemurafenib—skin cancer	0.00225	0.00374	CcSEcCtD
Plerixafor—Hypersensitivity—Imiquimod—skin cancer	0.00225	0.00373	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00225	0.0236	CbGpPWpGaD
Plerixafor—Headache—Vemurafenib—skin cancer	0.00224	0.00372	CcSEcCtD
Plerixafor—Erythema—Temozolomide—skin cancer	0.00224	0.00372	CcSEcCtD
Plerixafor—Discomfort—Bleomycin—skin cancer	0.00223	0.00371	CcSEcCtD
Plerixafor—Malaise—Dactinomycin—skin cancer	0.00223	0.00371	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RHOU—skin cancer	0.00223	0.0235	CbGpPWpGaD
Plerixafor—Asthenia—Imiquimod—skin cancer	0.00219	0.00363	CcSEcCtD
Plerixafor—Anaphylactic shock—Bleomycin—skin cancer	0.00217	0.0036	CcSEcCtD
Plerixafor—Pruritus—Imiquimod—skin cancer	0.00216	0.00358	CcSEcCtD
Plerixafor—Nausea—Vemurafenib—skin cancer	0.00213	0.00353	CcSEcCtD
Plerixafor—Diarrhoea—Imiquimod—skin cancer	0.00209	0.00346	CcSEcCtD
Plerixafor—Discomfort—Dactinomycin—skin cancer	0.00208	0.00346	CcSEcCtD
Plerixafor—Ill-defined disorder—Temozolomide—skin cancer	0.00208	0.00345	CcSEcCtD
Plerixafor—Erythema—Fluorouracil—skin cancer	0.00206	0.00343	CcSEcCtD
Plerixafor—Malaise—Temozolomide—skin cancer	0.00202	0.00335	CcSEcCtD
Plerixafor—Dizziness—Imiquimod—skin cancer	0.00202	0.00335	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00197	0.00328	CcSEcCtD
Plerixafor—Paraesthesia—Bleomycin—skin cancer	0.00195	0.00323	CcSEcCtD
Plerixafor—Vomiting—Imiquimod—skin cancer	0.00194	0.00322	CcSEcCtD
Plerixafor—Dyspnoea—Bleomycin—skin cancer	0.00193	0.00321	CcSEcCtD
Plerixafor—Rash—Imiquimod—skin cancer	0.00192	0.00319	CcSEcCtD
Plerixafor—Dermatitis—Imiquimod—skin cancer	0.00192	0.00319	CcSEcCtD
Plerixafor—Headache—Imiquimod—skin cancer	0.00191	0.00317	CcSEcCtD
Plerixafor—Arthralgia—Temozolomide—skin cancer	0.00191	0.00317	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—ERCC2—skin cancer	0.0019	0.02	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00189	0.00314	CcSEcCtD
Plerixafor—Discomfort—Temozolomide—skin cancer	0.00188	0.00313	CcSEcCtD
Plerixafor—Dry mouth—Temozolomide—skin cancer	0.00187	0.0031	CcSEcCtD
Plerixafor—Pain—Bleomycin—skin cancer	0.00185	0.00308	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—SHH—skin cancer	0.00185	0.0195	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PTCH2—skin cancer	0.00185	0.0194	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00184	0.00306	CcSEcCtD
Plerixafor—Anaphylactic shock—Temozolomide—skin cancer	0.00183	0.00303	CcSEcCtD
Plerixafor—Nausea—Imiquimod—skin cancer	0.00181	0.00301	CcSEcCtD
Plerixafor—Nervous system disorder—Temozolomide—skin cancer	0.00179	0.00298	CcSEcCtD
Plerixafor—Feeling abnormal—Bleomycin—skin cancer	0.00179	0.00296	CcSEcCtD
Plerixafor—Skin disorder—Temozolomide—skin cancer	0.00178	0.00295	CcSEcCtD
Plerixafor—Hyperhidrosis—Temozolomide—skin cancer	0.00177	0.00293	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—PTCH1—skin cancer	0.00176	0.0185	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—SMO—skin cancer	0.00176	0.0185	CbGpPWpGaD
Plerixafor—Fatigue—Dactinomycin—skin cancer	0.00174	0.00289	CcSEcCtD
Plerixafor—Discomfort—Fluorouracil—skin cancer	0.00174	0.00288	CcSEcCtD
Plerixafor—Pain—Dactinomycin—skin cancer	0.00173	0.00287	CcSEcCtD
Plerixafor—Urticaria—Bleomycin—skin cancer	0.00172	0.00286	CcSEcCtD
Plerixafor—Haemoglobin—Docetaxel—skin cancer	0.00172	0.00285	CcSEcCtD
Plerixafor—Haemorrhage—Docetaxel—skin cancer	0.00171	0.00284	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—PTGER4—skin cancer	0.00171	0.018	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Fluorouracil—skin cancer	0.00168	0.0028	CcSEcCtD
Plerixafor—Connective tissue disorder—Docetaxel—skin cancer	0.00168	0.00279	CcSEcCtD
Plerixafor—Feeling abnormal—Dactinomycin—skin cancer	0.00167	0.00276	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00167	0.00276	CcSEcCtD
Plerixafor—Insomnia—Temozolomide—skin cancer	0.00165	0.00274	CcSEcCtD
Plerixafor—Gastrointestinal pain—Dactinomycin—skin cancer	0.00165	0.00274	CcSEcCtD
Plerixafor—Nervous system disorder—Fluorouracil—skin cancer	0.00165	0.00274	CcSEcCtD
Plerixafor—Paraesthesia—Temozolomide—skin cancer	0.00164	0.00272	CcSEcCtD
Plerixafor—Dyspnoea—Temozolomide—skin cancer	0.00163	0.00271	CcSEcCtD
Plerixafor—Dyspepsia—Temozolomide—skin cancer	0.00161	0.00267	CcSEcCtD
Plerixafor—Abdominal pain—Dactinomycin—skin cancer	0.0016	0.00265	CcSEcCtD
Plerixafor—Hypersensitivity—Bleomycin—skin cancer	0.0016	0.00265	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Temozolomide—skin cancer	0.00158	0.00262	CcSEcCtD
Plerixafor—Fatigue—Temozolomide—skin cancer	0.00158	0.00262	CcSEcCtD
Plerixafor—Pain—Temozolomide—skin cancer	0.00156	0.00259	CcSEcCtD
Plerixafor—Constipation—Temozolomide—skin cancer	0.00156	0.00259	CcSEcCtD
Plerixafor—Asthenia—Bleomycin—skin cancer	0.00156	0.00258	CcSEcCtD
Plerixafor—Immune system disorder—Docetaxel—skin cancer	0.00155	0.00257	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00153	0.00255	CcSEcCtD
Plerixafor—Pruritus—Bleomycin—skin cancer	0.00153	0.00254	CcSEcCtD
Plerixafor—Insomnia—Fluorouracil—skin cancer	0.00152	0.00253	CcSEcCtD
Plerixafor—Paraesthesia—Fluorouracil—skin cancer	0.00151	0.00251	CcSEcCtD
Plerixafor—Feeling abnormal—Temozolomide—skin cancer	0.00151	0.0025	CcSEcCtD
Plerixafor—Dyspnoea—Fluorouracil—skin cancer	0.0015	0.00249	CcSEcCtD
Plerixafor—Mental disorder—Docetaxel—skin cancer	0.0015	0.00249	CcSEcCtD
Plerixafor—Gastrointestinal pain—Temozolomide—skin cancer	0.0015	0.00248	CcSEcCtD
Plerixafor—Erythema—Docetaxel—skin cancer	0.00149	0.00247	CcSEcCtD
Plerixafor—Hypersensitivity—Dactinomycin—skin cancer	0.00149	0.00247	CcSEcCtD
Plerixafor—Dyspepsia—Fluorouracil—skin cancer	0.00148	0.00246	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—MC1R—skin cancer	0.00147	0.0155	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00145	0.00241	CcSEcCtD
Plerixafor—Urticaria—Temozolomide—skin cancer	0.00145	0.00241	CcSEcCtD
Plerixafor—Asthenia—Dactinomycin—skin cancer	0.00145	0.00241	CcSEcCtD
Plerixafor—Abdominal pain—Temozolomide—skin cancer	0.00145	0.0024	CcSEcCtD
Plerixafor—Pain—Fluorouracil—skin cancer	0.00144	0.00239	CcSEcCtD
Plerixafor—Feeling abnormal—Fluorouracil—skin cancer	0.00139	0.0023	CcSEcCtD
Plerixafor—Diarrhoea—Dactinomycin—skin cancer	0.00138	0.0023	CcSEcCtD
Plerixafor—Vomiting—Bleomycin—skin cancer	0.00138	0.00229	CcSEcCtD
Plerixafor—Rash—Bleomycin—skin cancer	0.00137	0.00227	CcSEcCtD
Plerixafor—Dermatitis—Bleomycin—skin cancer	0.00137	0.00227	CcSEcCtD
Plerixafor—Hypersensitivity—Temozolomide—skin cancer	0.00135	0.00224	CcSEcCtD
Plerixafor—Urticaria—Fluorouracil—skin cancer	0.00134	0.00222	CcSEcCtD
Plerixafor—Syncope—Docetaxel—skin cancer	0.00134	0.00222	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—MC1R—skin cancer	0.00133	0.014	CbGpPWpGaD
Plerixafor—Asthenia—Temozolomide—skin cancer	0.00131	0.00218	CcSEcCtD
Plerixafor—Loss of consciousness—Docetaxel—skin cancer	0.00131	0.00217	CcSEcCtD
Plerixafor—Pruritus—Temozolomide—skin cancer	0.00129	0.00215	CcSEcCtD
Plerixafor—Nausea—Bleomycin—skin cancer	0.00129	0.00214	CcSEcCtD
Plerixafor—Vomiting—Dactinomycin—skin cancer	0.00129	0.00213	CcSEcCtD
Plerixafor—Rash—Dactinomycin—skin cancer	0.00127	0.00212	CcSEcCtD
Plerixafor—Arthralgia—Docetaxel—skin cancer	0.00127	0.0021	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00126	0.00209	CcSEcCtD
Plerixafor—Diarrhoea—Temozolomide—skin cancer	0.00125	0.00208	CcSEcCtD
Plerixafor—Hypersensitivity—Fluorouracil—skin cancer	0.00124	0.00206	CcSEcCtD
Plerixafor—Dry mouth—Docetaxel—skin cancer	0.00124	0.00206	CcSEcCtD
Plerixafor—Anaphylactic shock—Docetaxel—skin cancer	0.00122	0.00202	CcSEcCtD
Plerixafor—Dizziness—Temozolomide—skin cancer	0.00121	0.00201	CcSEcCtD
Plerixafor—Nausea—Dactinomycin—skin cancer	0.0012	0.00199	CcSEcCtD
Plerixafor—Shock—Docetaxel—skin cancer	0.0012	0.00199	CcSEcCtD
Plerixafor—Nervous system disorder—Docetaxel—skin cancer	0.00119	0.00198	CcSEcCtD
Plerixafor—Pruritus—Fluorouracil—skin cancer	0.00119	0.00198	CcSEcCtD
Plerixafor—Skin disorder—Docetaxel—skin cancer	0.00118	0.00196	CcSEcCtD
Plerixafor—CXCR4—Disease—CSPG4—skin cancer	0.00118	0.0124	CbGpPWpGaD
Plerixafor—Vomiting—Temozolomide—skin cancer	0.00116	0.00193	CcSEcCtD
Plerixafor—Rash—Temozolomide—skin cancer	0.00115	0.00191	CcSEcCtD
Plerixafor—Diarrhoea—Fluorouracil—skin cancer	0.00115	0.00191	CcSEcCtD
Plerixafor—Dermatitis—Temozolomide—skin cancer	0.00115	0.00191	CcSEcCtD
Plerixafor—Headache—Temozolomide—skin cancer	0.00115	0.0019	CcSEcCtD
Plerixafor—Dizziness—Fluorouracil—skin cancer	0.00111	0.00185	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00111	0.00184	CcSEcCtD
Plerixafor—Insomnia—Docetaxel—skin cancer	0.0011	0.00182	CcSEcCtD
Plerixafor—Paraesthesia—Docetaxel—skin cancer	0.00109	0.00181	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PTCH2—skin cancer	0.00109	0.0115	CbGpPWpGaD
Plerixafor—Nausea—Temozolomide—skin cancer	0.00109	0.0018	CcSEcCtD
Plerixafor—Dyspnoea—Docetaxel—skin cancer	0.00108	0.0018	CcSEcCtD
Plerixafor—Vomiting—Fluorouracil—skin cancer	0.00107	0.00178	CcSEcCtD
Plerixafor—Dyspepsia—Docetaxel—skin cancer	0.00107	0.00178	CcSEcCtD
Plerixafor—Rash—Fluorouracil—skin cancer	0.00106	0.00176	CcSEcCtD
Plerixafor—Dermatitis—Fluorouracil—skin cancer	0.00106	0.00176	CcSEcCtD
Plerixafor—Headache—Fluorouracil—skin cancer	0.00106	0.00175	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Docetaxel—skin cancer	0.00105	0.00174	CcSEcCtD
Plerixafor—Fatigue—Docetaxel—skin cancer	0.00105	0.00174	CcSEcCtD
Plerixafor—Pain—Docetaxel—skin cancer	0.00104	0.00173	CcSEcCtD
Plerixafor—Constipation—Docetaxel—skin cancer	0.00104	0.00173	CcSEcCtD
Plerixafor—Feeling abnormal—Docetaxel—skin cancer	0.001	0.00166	CcSEcCtD
Plerixafor—Nausea—Fluorouracil—skin cancer	0.001	0.00166	CcSEcCtD
Plerixafor—Gastrointestinal pain—Docetaxel—skin cancer	0.000994	0.00165	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PTGER4—skin cancer	0.000966	0.0102	CbGpPWpGaD
Plerixafor—Abdominal pain—Docetaxel—skin cancer	0.000961	0.0016	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—SHH—skin cancer	0.000951	0.01	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—SMO—skin cancer	0.000902	0.00948	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PTCH1—skin cancer	0.000902	0.00948	CbGpPWpGaD
Plerixafor—Hypersensitivity—Docetaxel—skin cancer	0.000896	0.00149	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PTGER4—skin cancer	0.000878	0.00923	CbGpPWpGaD
Plerixafor—Asthenia—Docetaxel—skin cancer	0.000872	0.00145	CcSEcCtD
Plerixafor—Pruritus—Docetaxel—skin cancer	0.00086	0.00143	CcSEcCtD
Plerixafor—Diarrhoea—Docetaxel—skin cancer	0.000832	0.00138	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GLI2—skin cancer	0.000826	0.00869	CbGpPWpGaD
Plerixafor—Dizziness—Docetaxel—skin cancer	0.000804	0.00133	CcSEcCtD
Plerixafor—CXCR4—Disease—SHH—skin cancer	0.000802	0.00844	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ENO2—skin cancer	0.000802	0.00844	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MC1R—skin cancer	0.000788	0.00829	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GLI1—skin cancer	0.000777	0.00817	CbGpPWpGaD
Plerixafor—Vomiting—Docetaxel—skin cancer	0.000773	0.00128	CcSEcCtD
Plerixafor—Rash—Docetaxel—skin cancer	0.000767	0.00127	CcSEcCtD
Plerixafor—Dermatitis—Docetaxel—skin cancer	0.000766	0.00127	CcSEcCtD
Plerixafor—Headache—Docetaxel—skin cancer	0.000762	0.00126	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SUFU—skin cancer	0.000737	0.00775	CbGpPWpGaD
Plerixafor—Nausea—Docetaxel—skin cancer	0.000722	0.0012	CcSEcCtD
Plerixafor—CXCR4—Disease—FOXO4—skin cancer	0.000654	0.00688	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SHH—skin cancer	0.000562	0.00591	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RASA1—skin cancer	0.000558	0.00587	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SMO—skin cancer	0.000533	0.0056	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTCH1—skin cancer	0.000533	0.0056	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTGER4—skin cancer	0.000518	0.00545	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERCC2—skin cancer	0.000466	0.0049	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FOXO4—skin cancer	0.000458	0.00482	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TERT—skin cancer	0.000437	0.00459	CbGpPWpGaD
Plerixafor—CXCR4—Disease—BRAF—skin cancer	0.000346	0.00364	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—skin cancer	0.000306	0.00322	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—skin cancer	0.000279	0.00294	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—skin cancer	0.000258	0.00271	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BRAF—skin cancer	0.000242	0.00255	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—skin cancer	0.000222	0.00233	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRAS—skin cancer	0.000217	0.00229	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—skin cancer	0.000189	0.00198	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—skin cancer	0.000187	0.00197	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—skin cancer	0.00018	0.0019	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—skin cancer	0.000159	0.00167	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—skin cancer	0.000152	0.0016	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—skin cancer	0.000152	0.0016	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—skin cancer	0.000131	0.00138	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—skin cancer	0.000116	0.00122	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—skin cancer	0.000111	0.00117	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—skin cancer	0.000107	0.00112	CbGpPWpGaD
